Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients.

@article{Torregrosa2010OpenlabelTE,
  title={Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients.},
  author={Jos{\'e} Vicente Torregrosa and David Fuster and M. Gentil and Roberto Marc{\'e}n and Lu{\'i}s Guirado and Sof{\'i}a Z{\'a}rraga and Juan Carlos Vila Bravo and Dolores Burgos and Ana Monegal and {\'A}frica Mux{\'i} and Sagrario Garc{\'i}a},
  journal={Transplantation},
  year={2010},
  volume={89 12},
  pages={1476-81}
}
BACKGROUND Treatment with oral risedronate to prevent bone mineral density (BMD) loss in renal transplant recipients has been shown to be effective. There is no agreement on the optimum moment of introduction or how long it should be continued. The aim was to evaluate the effectiveness of risedronate at doses of 35 mg/week in renal transplant recipients who underwent treatment immediately after transplant. METHODS A randomized clinical trial was performed on 101 renal transplant patients. The… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…